The Scientist

» Duchenne muscular dystrophy

Most Recent

image: CRISPR Restores Muscle Function in Mice

CRISPR Restores Muscle Function in Mice

By | July 17, 2017

Scientists use the gene-editing tool to treat animals with a rare form of congenital muscular dystrophy.

0 Comments

Adding RNA sequencing analysis to genomic sequencing helps scientists uncover mutations likely responsible for genetic disorders they might otherwise miss.

0 Comments

image: CRISPR Corrects Duchenne-Causing Mutations

CRISPR Corrects Duchenne-Causing Mutations

By | April 12, 2017

Using CRISPR-Cpf1 gene editing, researchers have fixed mutations that cause a form of muscular dystrophy in cultured human cardiomyocytes and a mouse model.

0 Comments

image: Conditional FDA Approval for Fatal-Disease Drug

Conditional FDA Approval for Fatal-Disease Drug

By | September 19, 2016

The agency OKs Sarepta Therapeutics’s treatment for Duchenne muscular dystrophy through its accelerated approval pathway, which requires a confirmatory clinical trial.

0 Comments

image: Another Fatal-Disease Drug in Limbo

Another Fatal-Disease Drug in Limbo

By | April 26, 2016

A federal advisory panel votes against Sarepta Therapeutics’s treatment for Duchenne muscular dystrophy.

0 Comments

image: First Data from Anti-Aging Gene Therapy

First Data from Anti-Aging Gene Therapy

By | April 25, 2016

A biotech company reports that an experimental treatment elongated its CEO’s telomeres. 

8 Comments

image: CRISPR Improves Disease in Adult Mice

CRISPR Improves Disease in Adult Mice

By | January 4, 2016

Three groups of researchers used the gene-editing method to restore a protein deficient in Duchenne muscular dystrophy.

1 Comment

image: CRISPR Therapy in a Dish

CRISPR Therapy in a Dish

By | December 8, 2015

Redirecting the gene-editing tool to modulate gene expression, researchers restore protein function in cells from a child with Duchenne muscular dystrophy.

1 Comment

image: Fatal-Disease Drug in Limbo

Fatal-Disease Drug in Limbo

By | November 25, 2015

A panel of experts advised the US Food and Drug Administration that BioMarin Pharmaceutical has not demonstrated efficacy of its new drug for Duchenne muscular dystrophy.

0 Comments

image: (Re)Programming Director

(Re)Programming Director

By | October 1, 2012

Unwilling to accept the finality of terminal differentiation, Helen Blau has honed techniques that showcase the flexibility of cells to adopt different identities.

0 Comments

Popular Now

  1. Major German Universities Cancel Elsevier Contracts
  2. Running on Empty
    Features Running on Empty

    Regularly taking breaks from eating—for hours or days—can trigger changes both expected, such as in metabolic dynamics and inflammation, and surprising, as in immune system function and cancer progression.

  3. Most of Human Genome Nonfunctional: Study
  4. Identifying Predatory Publishers
AAAS